enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. FDA approves 1st new drug for schizophrenia in more ... - AOL

   www.aol.com/fda-approves-1st-drug-schizophrenia...

   Jake Goodman, MD, MBA is a psychiatry resident physician and a member of the ABC News Medical Unit. FDA approves 1st new drug for schizophrenia in more than 30 years originally appeared on abcnews ...

3. This FDA-approved drug promises a new way to treat schizophrenia

   www.aol.com/fda-approved-drug-promises-way...

   The nonprofit Institute for Clinical and Economic Review, which analyzes drug prices, said in January that the drug would be cost effective if priced between $16,000 and $20,000 per year.

4. Bristol Myers wins US FDA approval for new type of ...

   www.aol.com/news/us-fda-approves-bristol-myers...

   (Reuters) -The U.S. Food and Drug Administration approved Bristol Myers Squibb's schizophrenia drug late on Thursday, making it the first new type of antipsychotic medicine in decades. The ...

5. Xanomeline/trospium chloride - Wikipedia

   en.wikipedia.org/wiki/Xanomeline/trospium_chloride

   In September 2024, it was approved for medical use in the United States. [1] [2] It is the first antipsychotic drug approved by the US Food and Drug Administration (FDA) to treat schizophrenia that targets cholinergic receptors as opposed to dopamine receptors, which has long been the standard of care. [2] [3]

6. A promising schizophrenia drug showed mixed results. What ...

   lite.aol.com/news/world/story/0001/20241031/37d...

   Some people who took a new schizophrenia drug for a year improved with only a few side effects, but many dropped out of the research, the company announced Thursday. The results underscore the difficulties in treating schizophrenia, a severe mental illness that can cause people to hear voices, feel paranoid and withdraw from others.

7. Ulotaront - Wikipedia

   en.wikipedia.org/wiki/Ulotaront

   The Brief Negative Symptom Scale (BNSS) has been used to assess the effect of Ulotaront on the negative symptoms of schizophrenia. [16] In July 2023, the pharmaceutical company behind the drug announced that the drug had failed to outperform placebo in the treatment of acutely psychotic patients with schizophrenia, as measured by the PANSS. [17]